Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| K01DA061444 | U.S. NIH Grant/Contract | View source | |
| NCI-2026-01493 | Registry Identifier | CTRP (Clinical Trial Reporting Program) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
This randomized, double-blind, crossover human laboratory study compares the abuse liability of cigarettes containing menthol and non-menthol cigarette variants, using the participant's usual brand menthol cigarette as a within-subject reference. Participants complete standardized laboratory smoking sessions, behavioral economic tasks, and a naturalistic observational period. The study examines differences in nicotine delivery, smoking behavior, and subjective effects across cigarette types in laboratory and real-world contexts.
Participants complete a three-phase protocol over approximately three weeks, comprising five in-person laboratory visits and two one-week daily-diary periods.
In Phase 1, participants attend a 3-hour baseline laboratory visit after a 12-hour abstinence from nicotine, tobacco, and smoked cannabis. They smoke one usual brand menthol cigarette (UBMC) in a standardized session (10 puffs over 5 minutes) while puff topography is recorded. Serial 3 mL blood samples are collected at -5, +5, +15, +30, and +60 minutes relative to smoking initiation. Subjective effects (e.g., product appeal, sensory perception, craving) are assessed before and after smoking, followed by the Cigarette Purchase Task (CPT). Participants then complete brief surveys three times daily for one week to capture product use and subjective effects in the natural environment.
In Phase 2, participants return for three additional laboratory visits, each separated by at least 48 hours, and smoke one of three blinded study products in a randomized order; study coordinators remain blinded. Each visit follows the Phase 1 procedures (standardized smoking session, topography, serial blood sampling, and subjective ratings). After smoking, participants complete the CPT and the Cross-Price Elasticity Task (CPET), in which the price of UBMC increases while the study product remains fixed, characterizing substitutability.
In Phase 3, participants identify their preferred study product and receive a one-week supply, with instructions to use it exclusively in place of their UBMC. They continue the three-times-daily survey schedule throughout the week. The phase concludes with a final 2-hour laboratory visit including a remaining-cigarette count and the Progressive Ratio Task (PRT), providing a measure of the relative reinforcing value of the preferred study product vs. UBMC.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study Cigarette A | Experimental | Participants smoke one Study Cigarette A during one Phase 2 laboratory session (10 puffs over 5 minutes), with puff topography and serial plasma nicotine sampling. Subjective effects, the Cigarette Purchase Task, and the Cross-Price Elasticity Task are completed during the session. Order of exposure to Study Cigarettes A, B, and C is randomized. |
|
| Study Cigarette B | Experimental | Participants smoke one Study Cigarette B during one Phase 2 laboratory session (10 puffs over 5 minutes), with puff topography and serial plasma nicotine sampling. Subjective effects, the Cigarette Purchase Task, and the Cross-Price Elasticity Task are completed during the session. Order of exposure to Study Cigarettes A, B, and C is randomized. |
|
| Study Cigarette C | Experimental | Participants smoke one Study Cigarette C during one Phase 2 laboratory session (10 puffs over 5 minutes), with puff topography and serial plasma nicotine sampling. Subjective effects, the Cigarette Purchase Task, and the Cross-Price Elasticity Task are completed during the session. Order of exposure to Study Cigarettes A, B, and C is randomized. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biospecimen Collection | Behavioral | Exhaled carbon monoxide breath testing and serial 3 mL blood samples collected via indwelling intravenous catheter at -5, +5, +15, +30, and +60 minutes relative to smoking initiation during each laboratory visit. |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma nicotine (Cmax) | Nicotine delivery will be summarized by Cmax, the maximum nicotine concentration observed in the plasma samples for each participant. | During Phase 1 and 2 smoking sessions, assessed up to 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Appeal ratings (Labeled Hedonic Scale) | The Labeled Hedonic Scale (LHS) is a self-reported measure of appeal. Scores range from -100 (most disliked imaginable) to 100 (most liked imaginable) with higher scores indicating a greater degree of liking. | During Phase 1 and 2 smoking sessions and Phase 1 and 3 EMA, assessed up to 3 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| The Ohio State University Comprehensive Cancer Center | Contact | 800-293-5066 | OSUCCCClinicaltrials@osumc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Yoo Jin Cho, PhD, MPH | Ohio State University Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States |
Not provided
| Label | URL |
|---|---|
| The Jamesline | View source |
Not provided
De-identified individual participant data will be archived through the National Addiction & HIV Data Archive Program (NAHDAP) at the Inter-university Consortium for Political and Social Research (ICPSR). Access requires a Restricted Data Use Agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
Participants complete three blinded laboratory sessions in randomized order in which they smoke each of three study cigarettes in Phase 2, with sessions separated by at least 48 hours.
Not provided
Not provided
Study cigarettes are provided in identical, unmarked packaging. Participants and study coordinators involved in data collection are blinded to product assignment.
| Questionnaire Administration | Behavioral | Self-report questionnaires administered at laboratory visits to assess the subjective effects of each cigarette (e.g., product appeal, sensory perception, satisfaction) using validated instruments such as the Modified Cigarette Evaluation Questionnaire. |
|
| Cigarette Purchase Task | Behavioral | A behavioral economic task administered after each laboratory smoking session. Participants indicate how many cigarettes they would purchase across varying price points to characterize demand for each study product. |
|
| Cross-Price Elasticity Task | Behavioral | A behavioral economic task administered after each Phase 2 smoking session. Participants choose between their usual brand menthol cigarette (price increasing) and the study product (fixed price), characterizing substitutability. |
|
| Daily Diary Surveys | Behavioral | Brief electronic surveys completed three times daily for one week during Phase 1 (usual brand cigarette use) and Phase 3 (preferred study cigarette use), capturing product use, craving, withdrawal, mood, and subjective effects in the natural environment. |
|
| Progressive Ratio Task | Behavioral | A concurrent choice task administered at the final laboratory visit. |
|
| Puff topography |
Puffing topography will be summarized with total puff count, average puff duration, average inter-puff interval, average puff volume, total puff volume, average flow rate, and peak flow rate. |
| During Phase 1 and 2 smoking sessions, assessed up to 3 weeks |
| Sensory effects (general Labeled Magnitude Scale) | The general Labeled Magnitude Scale (gLMS) is a 5-item self-report measure of sensory effects. Scores range from 0 (no sensation) to 100 (strongest imaginable) with higher scores indicating a greater sensation intensity. | During Phase 1 and 2 smoking sessions and Phase 1 and 3 EMA, assessed up to 3 weeks |
| Nicotine craving and withdrawal (Questionnaire of smoking urges) | Craving relief will be assessed using Questionnaire of Smoking Urges (QSU). The QSU is made up of 10 statements about the respondent's feelings and thoughts about desire to smoke cigarettes as they are completing the questionnaire. The scoring comprises of two factors, each the sum of 5 items. The scores for each factor range from 5-35, and the total score (the sum of all 10 items) ranges from 10-70. For each factor and for the total score, higher scores indicate more severe urges. | During Phase 1 and 2 smoking sessions and Phase 1 and 3 EMA, assessed up to 3 weeks |
| Nicotine craving and withdrawal (Minnesota Nicotine Withdrawal Scale) | Withdrawal will be assessed using Minnesota Nicotine Withdrawal Scale (MNWS). Items are rated on a 5-point scale from 0 (none) to 4 (severe). MNWS is the sum of 8 items with scores ranging from 0 to 32 with higher scores indicating more severe overall withdrawal. | During Phase 1 and 2 smoking sessions and Phase 1 and 3 EMA, assessed up to 3 weeks |
| Nicotine craving and withdrawal (Minnesota Nicotine Withdrawal Scale) | MNWS-Craving will be calculated which uses a single item from the MNWS that is scored from 0-4 with higher scores indicating greater craving. | During Phase 1 and 2 smoking sessions and Phase 1 and 3 EMA, assessed up to 3 weeks |
| Breakpoint | Breakpoint will be defined as the first price at which cigarette consumption is zero during the Cigarette Purchase Task (CPT). | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Demand intensity (Q0) | Demand intensity will be defined as cigarette consumption at the lowest cigarette price of $0 during the Cigarette Purchase Task (CPT). | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Maximum financial expenditure on cigarettes (Omax) | Participants' reported consumption across different price points from the Cigarette Purchase Task (CPT) will be used to determine the maximum financial expenditure. | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Price at which expenditure is maximized (Pmax) | Participants' reported consumption across different price points from the Cigarette Purchase Task (CPT) will be used to determine the price at which expenditure is maximized. | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Demand elasticity (alpha) | Sensitivity of cigarette consumption to increase in price assessed using the Cigarette Purchase Task (CPT). | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Cross-over price | The price at which two options valued approximately equally will be calculated from the Cross Price Elasticity Task (CPET). | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Progressive ratio task | The proportion of puffs allocated to the study products versus usual brand menthol cigarettes (UBMC) will be measured with the Progressive Ratio Task (PRT). | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Preferred product selection | Count of participants selecting each of the 3 study products after completion of the 3 Phase 2 smoking sessions. | Post Phase 2 smoking sessions, assessed up to 3 weeks |
| Product substitution | Substitution assessed via use behavior during Phase 3 will be operationalized as the ratio of study product to UBMC used, with a ratio > 0 indicating any substitution and a ratio > 1 indicating substitution of study product for the UBMC at least 50% of the time. | 1 week Phase 3 substitution period |
| ID | Term |
|---|---|
| D014029 | Tobacco Use Disorder |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided